Home » Tysabri's 'Diminished Future Sales Potential'
Tysabri's 'Diminished Future Sales Potential'
Credit Suisse First Boston maintained a "neutral" rating for Biogen Idec after news reports claimed a fourth patient taking Tysabri contracted the potentially fatal brain disease PML. The Boston Globe reported that Biogen Idec informed the Food and Drug Administration that a patient may have contracted the rare brain disease after taking the multiple sclerosis drug pulled by Biogen Idec and partner Elan last February.
Forbes (http://www.forbes.com/business/healthcare/2005/06/02/0602automarketscan20.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May